PubRank

Ariane Mallat

Author PubWeight™ 47.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study. Radiology 2008 4.46
2 CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006 4.36
3 Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002 2.56
4 Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005 2.33
5 Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009 2.30
6 M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2013 2.16
7 Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011 2.14
8 Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005 2.07
9 Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012 2.01
10 [Assessment of hepatic fibrosis: what is the role of non-invasive markers in 2003?]. Gastroenterol Clin Biol 2003 1.99
11 Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2007 1.94
12 Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 2010 1.82
13 Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005 1.58
14 Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation. Radiology 2012 1.49
15 Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology 2011 1.41
16 Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009 1.25
17 The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J 2007 1.25
18 Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 2011 1.17
19 Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003 1.05
20 Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem 2002 0.93
21 Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology 2013 0.92
22 High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology 2011 0.92
23 Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis 2012 0.91
24 Molecular mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in human hepatic myofibroblasts. J Hepatol 2004 0.86
25 Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med 2002 0.85
26 [Fast appearance of intra-hepatic calcifications following a case of HELLP syndrome]. Gastroenterol Clin Biol 2002 0.81
27 Cigarette smoke exposure: a novel cofactor of NAFLD progression? J Hepatol 2009 0.81
28 Non-invasive assessment of liver graft fibrosis by transient elastography after liver transplantation. Clin Res Hepatol Gastroenterol 2013 0.81
29 Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int 2011 0.81
30 Transplantation for liver failure in patients with sickle cell disease: challenging but feasible. Liver Transpl 2011 0.80
31 [Microvacuolar steatosis following low doses of doxycycline]. Gastroenterol Clin Biol 2002 0.75
32 [Endocannabinoids: therapeutic perspectives in chronic liver diseases]. Gastroenterol Clin Biol 2007 0.75
33 [CB1 cannabinoid receptor antagonists: a novel approach for the treatment of liver fibrosis]. Med Sci (Paris) 2006 0.75